Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

69 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats.
Ceulemans LJ, Verbeke L, Decuypere JP, Farré R, De Hertogh G, Lenaerts K, Jochmans I, Monbaliu D, Nevens F, Tack J, Laleman W, Pirenne J. Ceulemans LJ, et al. PLoS One. 2017 Jan 6;12(1):e0169331. doi: 10.1371/journal.pone.0169331. eCollection 2017. PLoS One. 2017. PMID: 28060943 Free PMC article.
The following end-points were analyzed: 7-day survival; biomarkers of enterocyte viability (L-lactate, I-FABP); histology (morphologic injury to villi/crypts and villus length); intestinal permeability (Ussing chamber); endotoxin translocation (Lipopolysaccharide assay); c …
The following end-points were analyzed: 7-day survival; biomarkers of enterocyte viability (L-lactate, I-FABP); histology (morphologi …
Steroidal or non-steroidal FXR agonists - Is that the question?
Verbeke L, Nevens F, Laleman W. Verbeke L, et al. J Hepatol. 2017 Apr;66(4):680-681. doi: 10.1016/j.jhep.2017.01.013. Epub 2017 Jan 25. J Hepatol. 2017. PMID: 28131795 No abstract available.
Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions.
Laleman W, Verbeke L, Meersseman P, Wauters J, van Pelt J, Cassiman D, Wilmer A, Verslype C, Nevens F. Laleman W, et al. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):523-37; quiz 537. doi: 10.1586/egh.11.47. Expert Rev Gastroenterol Hepatol. 2011. PMID: 21780899 Review.
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W. Verbeke L, et al. Sci Rep. 2016 Sep 16;6:33453. doi: 10.1038/srep33453. Sci Rep. 2016. PMID: 27634375 Free PMC article.
Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Klein S, Rick J, Lehmann J, Schierwagen R, Schierwagen IG, Verbeke L, Hittatiya K, Uschner FE, Manekeller S, Strassburg CP, Wagner KU, Sayeski PP, Wolf D, Laleman W, Sauerbruch T, Trebicka J. Klein S, et al. Gut. 2017 Jan;66(1):145-155. doi: 10.1136/gutjnl-2015-309600. Epub 2015 Sep 17. Gut. 2017. PMID: 26385087
Reply: To PMID 24259407.
Verbeke L, Trebicka J, Laleman W. Verbeke L, et al. Hepatology. 2014 Nov;60(5):1799-800. doi: 10.1002/hep.27125. Epub 2014 May 9. Hepatology. 2014. PMID: 24623183 No abstract available.
The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.
Verbeke L, Farre R, Verbinnen B, Covens K, Vanuytsel T, Verhaegen J, Komuta M, Roskams T, Chatterjee S, Annaert P, Vander Elst I, Windmolders P, Trebicka J, Nevens F, Laleman W. Verbeke L, et al. Am J Pathol. 2015 Feb;185(2):409-19. doi: 10.1016/j.ajpath.2014.10.009. Epub 2015 Jan 12. Am J Pathol. 2015. PMID: 25592258
Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis.
Kerbert AJ, Verbeke L, Chiang FW, Laleman W, van der Reijden JJ, van Duijn W, Nevens F, Wolterbeek R, van Hoek B, Verspaget HW, Coenraad MJ. Kerbert AJ, et al. PLoS One. 2015 Sep 17;10(9):e0138264. doi: 10.1371/journal.pone.0138264. eCollection 2015. PLoS One. 2015. PMID: 26378453 Free PMC article.
RESULTS: Plasma copeptin concentration was significantly higher in cirrhotic rats than in controls (1.6 ± 0.5 vs. 0.9 ± 0.1 pmol/L, p< 0.01) and was negatively correlated to the mean arterial blood pressure (r = -0.574, p = 0.013). In cirrhotic patients, serum copeptin …
RESULTS: Plasma copeptin concentration was significantly higher in cirrhotic rats than in controls (1.6 ± 0.5 vs. 0.9 ± 0.1 pmol/L, p …
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats.
Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T, Nevens F, Laleman W. Verbeke L, et al. Hepatology. 2014 Jun;59(6):2286-98. doi: 10.1002/hep.26939. Epub 2014 Apr 14. Hepatology. 2014. PMID: 24259407
69 results
Jump to page
Feedback